Altmetric

Current and novel drug therapies for idiopathic pulmonary fibrosis

File Description SizeFormat 
Current and novel drug therapies for idiopathic pulmonary fibrosis.pdfPublished version388.27 kBAdobe PDFView/Open
Title: Current and novel drug therapies for idiopathic pulmonary fibrosis
Authors: Adamali, HI
Maher, TM
Item Type: Journal Article
Abstract: Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the aims of those treating IPF have shifted from reversing the disease to slowing or preventing progression of this chronic fibrotic illness. It is to be hoped that by slowing disease progression, survival will be improved from the current dismal median of 3.5 years following diagnosis. In Europe and Asia, a milestone has recently been reached with the licensing of the first IPF-specific drug, pirfenidone. This review assesses the current treatment modalities available for IPF, including pirfenidone. It also turns an eye to the future and discusses the growing number of promising compounds currently in development that it is hoped, in time, will make their way into the clinic as treatments for IPF.
Issue Date: 25-Sep-2012
Date of Acceptance: 24-Aug-2012
URI: http://hdl.handle.net/10044/1/63029
DOI: https://dx.doi.org/10.2147/DDDT.S29928
ISSN: 1177-8881
Publisher: Dove Medical Press
Start Page: 261
End Page: 271
Journal / Book Title: Drug Design, Development and Therapy
Volume: 6
Copyright Statement: © 2012 Adamali and Maher. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Keywords: Science & Technology
Life Sciences & Biomedicine
Chemistry, Medicinal
Pharmacology & Pharmacy
interstitial lung disease
pirfenidone
clinical trials
usual interstitial pneumonia
acute exacerbations
EPSTEIN-BARR-VIRUS
GROWTH-FACTOR-BETA
PLACEBO-CONTROLLED TRIAL
BLEOMYCIN HAMSTER MODEL
EPITHELIAL-MESENCHYMAL TRANSITION
ACID GASTROESOPHAGEAL-REFLUX
MEMBRANE-PROTEIN 1
N-ACETYLCYSTEINE
LUNG FIBROSIS
TGF-BETA
Acetylcysteine
Amino Acid Oxidoreductases
Animals
Antiviral Agents
Gastroesophageal Reflux
Humans
Idiopathic Pulmonary Fibrosis
Interleukin-13
Lung Transplantation
MicroRNAs
Protein Kinase Inhibitors
Pyridones
Transforming Growth Factor beta
1115 Pharmacology And Pharmaceutical Sciences
Publication Status: Published
Online Publication Date: 2012-09-26
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons